美股异动丨Tonix盘前涨超10%
Tonix Pharmaceuticals (US:TNXP) Ge Long Hui A P P·2025-08-18 08:27Group 1 - The core point of the article is that Tonix Pharmaceuticals (TNXP.US) experienced a pre-market increase of over 10% following the FDA's approval of its drug for treating chronic pain-related symptoms [1] Group 2 - The FDA approval is a significant milestone for Tonix, potentially enhancing its market position in the biopharmaceutical industry [1]